

**FAX**

Date: September 13, 2004  
To: Office of Initial Patent Examination's Filing Receipt  
Corrections  
Application #: 10/812,143  
Filing Date: 03/29/04  
Fax Number: 703-746-9195  
From: Rachel A. Polster  
cc:  
Pages: 2 (including cover sheet)

Pfizer Inc  
575 Maryville Centre Drive  
St. Louis, Missouri 63141  
tel 314.274.7354  
fax 314.274.9095  
rachel.a.polster@pfizer.com  
www.pfizer.com

The attached filing receipt shows our Power of Attorney customer number as 23913; however, the customer number at this St. Louis site is 26648. Applicant requests a corrected customer number for this application. Formal documentation will be mailed at a later date.

Rachel A. Polster  
47,004

**Confidentiality Note:** The documents accompanying this telecopy transmission contain information belonging to Pfizer Inc, which is intended only for the use of the addressee. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this telecopied information is strictly prohibited. If you have received this telecopy in error, please immediately notify us by telephone to arrange for the return of the original documents to us.



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/812,143	03/29/2004	1626	900	PO2037B		1	1

**RECEIVED**

SEP 07 2004

PHARMACIA  
GLOBAL PATENT DEPT.  
ST. LOUIS, MO

CONFIRMATION NO. 3239

UPDATED FILING RECEIPT



\*OC000000013694607\*


26648  
PHARMACIA CORPORATION  
GLOBAL PATENT DEPARTMENT  
POST OFFICE BOX 1027  
ST. LOUIS, MO 63006

Date Mailed: 09/01/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

**Applicant(s)**

Charlotte Moira Norfor Allerton, Residence Not Provided;  
David John Bull, Residence Not Provided;  
Mark Edward Bunnage, Residence Not Provided;  
Robert John Maguire, Residence Not Provided;  
John Steele, Residence Not Provided;

**Assignment For Published Patent Application**

Pfizer Inc., New York, NY

**Power of Attorney:** The patent practitioners associated with Customer Number ~~23913~~ 26648

**Domestic Priority data as claimed by applicant**

This application is a DIV of 10/348,881 01/22/2003 PAT 6,713,496  
which claims benefit of 60/362,377 03/06/2002

**Foreign Applications**

UNITED KINGDOM 0201389.4 01/22/2002  
UNITED KINGDOM 0202027.9 01/29/2002

**If Required, Foreign Filing License Granted:** 06/08/2004

**The number of your priority application, to be used for filing abroad under the Paris Convention is,**  
**US10/812,143**